Click on image to view ad details and full-size version on AdPharm

To see all of the ads from this campaign, click here
To see all of this brand’s ads on AdPharm, click here

Click on image to view ad details and full-size version on AdPharm

To see all of this brand’s ads on AdPharm, click here

If you can draw a map to every bathroom in town…

Today is the day to talk to your doctor about overactive bladder and Toviaz – a pill that comes with a plan

A pill for overactive bladder that comes with a plan

To see all of this brand’s ads on AdPharm, click here

Click on thumbnail to view the full-size ad on AdPharm

When planning a treatment course for DLBCL
Take the essential path toward improved survival

Rituxan + CHOP is proven to prolong survival in DLBCL

Brand name: Rituxan
Generic name/category: Rituximab, Monoclonal antibodies, Orphan drugs, Antineoplastic drugs
Company: Genentech BioOncology and Biogen idec
Country/Market: USA, North America
Indication(s)/use: diffuse large B cell lymphoma (DLBCL)
Target: Healthcare Professionals (HCP)
Tagline: Take the essential path toward improved survival
Medium: Print ad
Size/duration: single-page
Publication/Aired: Blood – August 6, 2009

To see all of this brand’s ads on AdPharm, click here

In a typical hemolytic uremic syndrome (aHUS)
Unregulated complement.
Unimaginable destruction.

Now recruiting patients for the first ever complement inhibitor trials for aHUS.

In medicine, hemolytic-uremic syndrome (or haemolytic-uraemic syndrome, abbreviated HUS) is a disease characterized by hemolytic anemia, acute renal failure (uremia) and a low platelet count (thrombocytopenia). It predominantly but not exclusively affects children. Most cases are preceded by an episode of diarrhea caused by E. coli O157:H7, which is acquired as a foodborne illness. It is a medical emergency and carries a 5???10% mortality; of the remainder, the majority recover without major consequences but a small proportion develop chronic kidney disease and become reliant on renal replacement therapy.

HUS was first defined as a syndrome in 1955.

More on Wikipedia

Generic name/category: Clinical trials
Company: Alexion Pharmaceuticals
Country/Market: USA, North America
Indication(s)/use: Atypical hemolytic uremic syndrome
Target: Healthcare Professionals (HCP)
Tagline: Innovators in complement inhibition
Medium: Print ad
Size/duration: single-page
Publication/Aired: Blood – August 13, 2009

To see all of this brand's ads on AdPharm, click here
0 views
Sep 17, 2009

Visit AdPharm.net for more pharmaceutical ads

Voici Abilify, indiqu?© dans le traitement de la schizophr?©nie.
Parce que les sympt??mes n?©gatifs font aussi partie de la route.

Une att?©nuation des sympt??mes positifs et n?©gatifs a ?©t?© d?©montr?©e avec Abilify.

Nouveau Abilify.

Here's Abilify, indicated for the treatment of schizophrenia.
Because negative symptoms are also part of the road.

New Abilify.

Aripiprazole (marketed as Abilify, Abilify Discmelt; also known as BMS 337039, OPC-14597, and APZ) was approved by the Food and Drug Administration (FDA) on November 15, 2002 for the treatment of schizophrenia, the sixth atypical antipsychotic medication of its kind. More recently, it received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder, and as an adjunct for the treatment of major depressive disorder. Aripiprazole was developed by Otsuka in Japan; in the U.S., Otsuka America markets the drug jointly with Bristol-Myers Squibb.

More on Wikipedia

Brand name: Abilify
Generic name/category: Aripiprazole, Atypical antipsychotics, Piperazines
Company: Bristol-Myers Squibb (BMS)
Country/Market: Canada, North America
Indication(s)/use: Schizophrenia
Target: Healthcare Professionals (HCP)
Medium: Print ad
Size/duration: double-page spread
Publication/Aired: Le M?©decin du Qu?©bec – September 2009

To see all of this brand's ads on AdPharm, click here
0 views
Sep 09, 2009

Visit AdPharm.net for more pharmaceutical ads

For the treatment of adults with major depressive disorder
SNRI Therapy… For your managed care formulary
Predictable kinetics
Predictable Dacon
Predictable cost

Desvenlafaxine succinate, marketed under the name Pristiq, is an antidepressant of the serotonin-norepinephrine reuptake inhibitor class from Wyeth. It is a metabolite of venlafaxine (Effexor). Although Wyeth touts the notion that Pristiq is being targeted as the first non-hormonal based treatment for menopause, in fact, the anticonvulsant medication gabapentin already owns this distinction.[

More on Wikipedia

Brand name: Pristiq
Generic name/category: desvenlafaxine
Company: Wyeth
Country/Market: USA, North America
Indication(s)/use: Major Depressive Disorder (MDD)
Target: Healthcare Professionals (HCP)
Tagline: Think beyond start
Publication: Pharmacy And Therapeutics May 2009